ACRX:NSD-AcelRx Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 1.54

Change

0.00 (0.00)%

Market Cap

USD 0.14B

Volume

1.50M

Average Target Price

USD 0.77 (-50.32%)
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-26 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

N/A

USD9.99B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 32.94 11.89
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CRON Cronos Group Inc

N/A

USD2.82B 44.31 N/A
PCRX Pacira BioSciences, Inc

N/A

USD2.75B 22.85 62.06
APHA Aphria Inc

N/A

USD2.03B 57.50 454.68
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.86B 16.83 13.97
ATNX Athenex, Inc

N/A

USD1.28B N/A N/A
ENDP Endo International plc

N/A

USD1.22B N/A 9.47
SUPN Supernus Pharmaceuticals, Inc

N/A

USD1.12B 8.62 5.57

ETFs Containing ACRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -27.01% 45% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.01% 45% F 17% F
Trailing 12 Months  
Capital Gain -12.50% 55% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.50% 55% F 29% F
Trailing 5 Years  
Capital Gain -72.60% 34% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.60% 34% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -11.70% N/A N/A 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.70% N/A N/A 16% F
Risk Return Profile  
Volatility (Standard Deviation) 38.84% N/A N/A 33% F
Risk Adjusted Return -30.13% N/A N/A 20% F
Market Capitalization 0.14B 41% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -2.72 54% F 67% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital N/A 100% A+ 100% A+
Return on Assets -34.11% 24% F 10% F
Debt to Equity Ratio -49.54% 76% C 95% A
Technical Ratios  
Short Ratio 5.61 50% F 30% F
Short Percent 8.95% 42% F 24% F
Beta 1.52 40% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector